Among non-serious mild AEs, increased eosinophil count and injection site erythema were more common in both IL-2 treatment groups compared to placebo, aligning with previous reports of known side effect of low-dose IL-2 immunotherapies in other clinical contexts [29, 32–34]. The gene discussed is IL2; the disease is Erythema.